31Jan 2021
Second-line tyrosine kinase inhibitors (TKIs) versus immunotherapy (IO) for advanced hepatocellular carcinoma (HCC): Real-world efficacy and safety analysis in patients with varying liver dysfunction.

Second-line tyrosine kinase inhibitors (TKIs) versus immunotherapy (IO) for advanced hepatocellular carcinoma (HCC): Real-world efficacy and safety analysis in patients with varying liver dysfunction.

Within the last 4 years, the FDA approved five drugs as second-line therapies for advanced HCC. At our cancer center, the majority of our patients are Hispanic with varying liver dysfunction, and this real world population is not represented in registration trials of TKIs and IOs

  • #oncology

Like

Save

Share